 | | Vol. 8.35 – 8 September, 2020 |
| |
|
|
| Differential expression analysis of 600 immune-related genes was performed on 207 pancreatic neuroendocrine tumors samples, comprising a training cohort and two validation cohorts from multiple transcriptome profiling platforms.
[Gut] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists investigated immunity in patients with inherited salt-losing tubulopathies (SLT). Forty-seven genotyped SLT patients were recruited.
[Nature Communications] |
|
|
|
| Researchers collected ATAC-seq, Hi-C, Capture Hi-C and nuclear RNA-seq data in stimulated CD4+ T cells over 24 hours, to identify functional enhancers regulating gene expression.
[Nature Communications] |
|
|
|
| Levels of immunoglobulin (Igs) in induced sputum, a more direct measure of airway Igs, are not well studied. Given the vital role Igs perform in microbial defence and tissue homeostasis, investigators assessed airway Igs in induced sputum of smokers and patients with chronic obstructive pulmonary disease.
[European Respiratory Journal] |
|
|
|
| Pancreatic ductal adenocarcinoma (PDAC) microarray and TCGA datasets were analyzed to identify cytokines and cognate receptors overexpressed in PDAC and associated with survival.
[Clinical Cancer Research] |
|
|
|
| Researchers demonstrated that prolonged cell cycle arrest at the G2-mitosis boundary from either excessive DNA damage or CDK1 inhibition prevented inflammatory-stimulated gene expression and immune-mediated destruction of distal tumors
[Cell Reports] |
|
|
|
| Investigators performed an integrative analysis of immune-related gene profiles from pretreatment biopsies and constructed the first individualized immune signature for pCR and outcome prediction of esophageal squamous cell carcinomas through a multicenter analysis.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Scientists initiated a Phase II study of natalizumab with corticosteroids for initial treatment of acute gastrointestinal graft-versus-host disease.
[Bone Marrow Transplantation] |
|
|
|
| Dual immunofluorescence using CD33 and VISTA antibodies was performed. VISTA expression positively correlated with CD33 expression in melanoma tissue.
[Scientific Reports] |
|
|
|
| The impact of tumor secreted exosomes on immune function in the tumor environment was investigated using exosomes isolated from gastric cancer cell lines MKN-28, MKN-45, and SGC-7901.
[Scientific Reports] |
|
|
|
| Investigators tested human erythropoietin-producing hepatocellular receptor tyrosine kinase class A2 directed CAR T cells for their capacity to target and kill human pediatric osteosarcoma and Ewing sarcoma tumor cells using in vitro and in vivo assays.
[Cancer Gene Therapy] |
|  |
|
|
|
| The development of different types of immunotherapies, including vaccines, and the use of pathogens, monoclonal antibodies, recombinant proteins, cytokines, and cellular immunotherapies, are changing the way in which we approach many diseases, especially cancer.
[Cellular & Molecular Immunology] |
|
|
|
|
| Avalon GloboCare Corp. announced the launch of its new allogeneic MSC therapeutic platform. Avalon plans to develop the MSC platform as a potential therapy for COVID-19, the disease caused by the SARS-CoV-2, and for bone marrow transplant related complications of acute graft versus host disease.
[Avalon GloboCare Corp. ] |
|
|
|
| Atara Biotherapeutics, Inc. announced that the FDA has accepted the Investigational New Drug application providing clearance to initiate an open-label, single-arm Phase I clinical study of ATA2271, the company’s next-generation autologous CAR T therapy targeting mesothelin under development in collaboration with Memorial Sloan Kettering Cancer Center, for the treatment of advanced mesothelioma.
[Atara Biotherapeutics, Inc.] |
|
|
|
| Autolus and CGT Catapult are collaborating to achieve approval for commercial manufacture of CAR-T cell therapies from the CGT Catapult manufacturing centre. The collaboration will enable the UK company to expand further and contribute to the global competitiveness of the UK cell and gene therapy industry.
[CGT Catapult ] |
|
|
|
|
| May 7-11, 2021
Castelnuovo Berardenga, Italy |
|
|
|
|
| | Terasaki Research Institute – Los Angeles, California, United States |
|
|
|
| | MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | STEMCELL Technologies – Flexible |
|
|
|
| | National Research Council – Ottowa, Ontario, Canada |
|
|
|
| | Princess Margaret Cancer Center – Toronto, Ontario, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
